Jim Simons Relmada Therapeutics, Inc. Transaction History

Renaissance Technologies LLC

$63.1 Billion
Q3 2024

A detailed history of Jim Simons (Renaissance Technologies LLC) transactions in Relmada Therapeutics, Inc. stock. As of the latest transaction made, Renaissance Technologies LLC holds 25,888 shares of RLMD stock, worth $72,486. This represents 0.0% of its overall portfolio holdings.

Number of Shares

25,888

Previous 88,775 70.84%

Holding current value

$72,486

Previous $266,000 68.8%

% of portfolio

0.0%

Previous 0.0%

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 13, 2024	SELL	$2.3 - $4.36 $144,640 - $274,187	-62,887 Reduced 70.84%	25,888 $83,000
Q2 2024 Aug 09, 2024	BUY	$2.93 - $4.94 $157,537 - $265,608	53,767 Added 153.58%	88,775 $266,000
Q1 2024 May 13, 2024	SELL	$3.1 - $6.8 $346,831 - $760,790	-111,881 Reduced 76.17%	35,008 $163,000
Q4 2023 Feb 13, 2024	BUY	$2.45 - $4.22 $199,954 - $344,411	81,614 Added 125.03%	146,889 $608,000
Q3 2023 Nov 14, 2023	SELL	$2.48 - $3.79 $167,392 - $255,813	-67,497 Reduced 50.84%	65,275 $196,000
Q2 2023 Aug 11, 2023	SELL	$2.22 - $3.54 $400,494 - $638,626	-180,403 Reduced 57.6%	132,772 $327,000
Q1 2023 May 12, 2023	BUY	$2.24 - $4.76 $213,617 - $453,937	95,365 Added 43.78%	313,175 $708,000
Q4 2022 Feb 13, 2023	BUY	$2.17 - $35.84 $472,647 - $7.81 Million	217,810 New	217,810 $760,000
Q1 2022 May 13, 2022	SELL	$16.72 - $26.99 $240,767 - $388,656	-14,400 Closed	0 $0
Q4 2021 Feb 11, 2022	SELL	$16.93 - $26.82 $18,623 - $29,502	-1,100 Reduced 7.1%	14,400 $324,000
Q3 2021 Nov 12, 2021	BUY	$21.86 - $34.77 $338,830 - $538,935	15,500 New	15,500 $406,000

Others Institutions Holding RLMD

# of Institutions

Shares Held

12.3M

Call Options Held

229K

Put Options Held

138K

View Full List

About RELMADA THERAPEUTICS, INC.

Ticker RLMD
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 28,608,500
Market Cap $80.1M
Description
Relmada Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing various products for the treatment of central nervous system (CNS) diseases and other disorders. Its lead product candidate is Esmethadone (d-methadone, dextromethadone, and REL-1017), a new chemical entity and N-methyl-D-aspartate receptor antagonist that ...

More about RLMD

Track Jim Simons's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Renaissance Technologies LLC, based on Form 13F filings with the SEC.

News

Stay updated on Renaissance Technologies LLC and Jim Simons with notifications on news.

Account